CANGENE BIOPHARMA, LLC

CANGENE BIOPHARMA, LLC specializes in the development, manufacturing, and quality control of biopharmaceutical products, with core capabilities centered on cell culture processes, viral vector production, aseptic filling, and downstream purification technologies. The company applies Good Manufacturing Practices (GMP) to support clinical and commercial-scale biologics, including monoclonal antibodies, recombinant proteins, and plasma-derived therapeutics. Technical expertise includes process validation, analytical method development, sterility assurance, and regulatory documentation aligned with FDA and EMA standards. Key differentiators lie in their focus on high-purity biologics manufacturing and end-to-end process scalability, particularly for complex modalities requiring stringent contamination control and cryogenic handling. No agency relationships can be inferred from available award data, as no recent contracts or agency-specific performance records are provided. Therefore, no patterns of engagement with federal departments or procurement offices can be confirmed. The primary NAICS code 325412 reflects active participation in the biologic and pharmaceutical manufacturing sector, with practical emphasis on therapeutic product development for public health applications. The company’s market positioning is grounded in contract manufacturing and process optimization for biologics, serving clients requiring compliant, scalable production infrastructure without direct commercial branding. CANGENE BIOPHARMA, LLC is structured as a limited liability company (2L) with its operational base in Baltimore, Maryland. The entity holds no government-recognized certifications such as 8(a), HUBZone, or SDVOSB, and its government market presence is defined solely by its technical manufacturing capabilities rather than socioeconomic program participation. Geographic footprint is confined to its Maryland facility, with no indication of multi-site operations or federal procurement network expansion.